CHMP5 and COVID-19: Currently, several neutralizing antibodies against spike protein RBD have been developed and granted emergency use authorization for COVID-19 treatment by the U.S. Food and Drug Administration: regdanvimab (Celltrion Healthcare, Inc., Incheon, Korea), casirivimab and imdevimab cocktail (Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA), and bamlanivimab and etesevimab cocktail (Eli Lilly and Company, Indianapolis, IN, USA).